Log in

NASDAQ:PRQR - ProQR Therapeutics Stock Price, Forecast & News

$7.18
+0.61 (+9.28 %)
(As of 03/29/2020 01:26 AM ET)
Today's Range
$6.06
Now: $7.18
$7.54
50-Day Range
$5.25
MA: $7.41
$9.12
52-Week Range
$4.83
Now: $7.18
$16.07
Volume249,749 shs
Average Volume214,348 shs
Market Capitalization$354.48 million
P/E RatioN/A
Dividend YieldN/A
Beta0.42
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
Read More
ProQR Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.13 per share

Profitability

Net Income$-63,260,000.00

Miscellaneous

Employees118
Market Cap$354.48 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.


ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

How has ProQR Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRQR stock has increased by 2.6% and is now trading at $7.18. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ProQR Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ProQR Therapeutics.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for ProQR Therapeutics.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics NV (NASDAQ:PRQR) released its earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.04. View ProQR Therapeutics' earnings history.

What price target have analysts set for PRQR?

3 brokerages have issued twelve-month target prices for ProQR Therapeutics' stock. Their forecasts range from $25.00 to $40.00. On average, they expect ProQR Therapeutics' stock price to reach $30.67 in the next year. This suggests a possible upside of 327.1% from the stock's current price. View analysts' price targets for ProQR Therapeutics.

Has ProQR Therapeutics been receiving favorable news coverage?

Media stories about PRQR stock have been trending very negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ProQR Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutProQR Therapeutics.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 688,800 shares, an increase of 17.6% from the February 27th total of 585,800 shares. Based on an average daily volume of 197,000 shares, the short-interest ratio is presently 3.5 days. Approximately 2.5% of the shares of the stock are sold short. View ProQR Therapeutics' Current Options Chain.

Who are some of ProQR Therapeutics' key competitors?

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include Bioamber (BIOA), GALAPAGOS NV/S (GLPG), Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Uniqure (QURE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Verastem (VSTM) and Progenics Pharmaceuticals (PGNX).

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:
  • Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 36)
  • Ms. Smital Shah, Chief Bus. & Financial Officer (Age 43)
  • Ms. Lisa A. Hayes, VP of Investor Relations & Corp. Communications
  • Mr. Bart Klein, Sr. VP of Intellectual Property
  • Mr. Gerard Platenburg, Chief Innovation Officer & Chairman of Advisory Board (Age 55)

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (6.79%), Jennison Associates LLC (5.33%), FMR LLC (2.39%), UBS Group AG (1.03%), Cowen AND Company LLC (0.21%) and Renaissance Technologies LLC (0.17%).

Which institutional investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, and Renaissance Technologies LLC.

Which institutional investors are buying ProQR Therapeutics stock?

PRQR stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Cowen AND Company LLC, UBS Group AG, California Public Employees Retirement System, Goldman Sachs Group Inc., Geode Capital Management LLC, Oxford Asset Management LLP, and Ellington Management Group LLC.

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $7.18.

How big of a company is ProQR Therapeutics?

ProQR Therapeutics has a market capitalization of $354.48 million. The biopharmaceutical company earns $-63,260,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. ProQR Therapeutics employs 118 workers across the globe. View additional information about ProQR Therapeutics.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is http://www.proqr.com/.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]


MarketBeat Community Rating for ProQR Therapeutics (NASDAQ PRQR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  547
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: CD Ladder

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel